Overview

• The NPPA has set retail price ceilings for 37 essential drug formulations, covering anti-inflammatories, antibiotics, cardiovascular, diabetes and psychiatric treatments.
• New maximum prices have been fixed for four emergency-use medicines—ipratropium, sodium nitroprusside, diltiazem and povidone iodine—to curb excessive charges in acute-care settings.
• Pharmaceutical manufacturers must submit updated Form V price lists via the Integrated Pharmaceutical Database Management System and notify state drug controllers.
• Retailers must prominently display the revised MRPs or face action under the Drugs (Prices Control) Order, 2013 and the Essential Commodities Act, including recovery of overcharged amounts plus interest.
• The notified ceilings exclude GST, which can only be added if legally applicable, and they supersede all prior price orders for the specified formulations.